Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin

Updated 04/30/2024

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03458260
Study type	Interventional
Source	The Lymphoma Academic Research Organisation
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 26, 2018
Completion date	March 2025

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01527045` - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Phase 2
	Completed	`NCT03161054` - Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas	Phase 2
	Recruiting	`NCT03246906` - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Phase 2
	Suspended	`NCT04231877` - Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Phase 1
	Active, not recruiting	`NCT00075478` - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 3
	Completed	`NCT00789776` - Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Phase 1/Phase 2
	Completed	`NCT01231412` - Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Phase 3
	Suspended	`NCT03704714` - Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma	Phase 1/Phase 2
	Active, not recruiting	`NCT03061188` - Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes	Phase 1
	Recruiting	`NCT01787409` - Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	N/A
	Active, not recruiting	`NCT03035331` - Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma	Phase 1/Phase 2
	Completed	`NCT00723099` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Phase 2
	Withdrawn	`NCT04372641` - Testing the Safety of CB-5339 in Patients With Cancer	Phase 1
	Recruiting	`NCT05336409` - A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies	Phase 1
	Active, not recruiting	`NCT03749018` - Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma	Phase 2
	Recruiting	`NCT05260957` - CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	Phase 2
	Completed	`NCT01251575` - Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	Phase 2